25% off our most popular buffers & solutions
Let Rockland's expertise in assay development guide you through the complexity of designing and developing an immunoassay. The Enzyme Immunoassay (EIA) displays a significant value and employs a wide range of methods to detect and quantitate analytes defined as either antigens or antibodies. Application of highly sensitive immunoassays allows for the rapid quantification of different analytes present at very low concentrations within a mixture of other substances with great sensitivity; providing valuable information that would otherwise be difficult to determine by other techniques.
Rockland's scientific expertise offer highly customized solutions to meet your basic, applied and clinical research demands in the development of unique in vitro assays. Our current services include western blot analyses, the development and evaluation of standard and specialized Enzyme Linked ImmunoSorbent Assays (ELISAs), Flow cytometry and Immunohistochemistry; all coordinated within a cGMP compliant manufacturing facility.
Rockland will collaborate with you to develop user-defined specifications, which become the basis for designing the immunoassay that meets or exceeds your overall research-relateddesign goals. The development of specific immunoassays can form part of an antibody development project or can be initiated using existing assay-specific reagents supplied by the client.
To further enable innovative biomarker development for drug discovery and diagnostic applications, we offer highly customized solutions to meet your basic, applied and clinical research demands. Whether it is the generation of highly specific antibodies or the development of unique in vitro assay systems, we can provide the scientific expertise and cGMP compliant manufacturing facilities necessary to support your biomarker evaluation and development needs.
Highly sensitive immunoassays use specialized antibodies for the testing and measurement of different biochemical substances, or analyte, in biological, virological, cellular secretion or drug studies at very low concentrations not detectable by other tests. We will collaborate with you to develop an assay to detect the analyte of your choosing.
The first step in the development of an immunoassay is the establishment of user-defined specifications. These become the basis for designing the immunoassay and facilitate the development of an immunoassay that meets or exceeds the overall research-related design goals of the user.
The result for this assay was that background and variability of blocker 1 incubated at room temperature for 2 hours were lowest compared to other blockers.
Adherent epithelial cells were fixed onto a plate and probed with primary antibody anti-GAPDH and detected by a secondary Dylight 488 coupled antibody.
Assessment of Antibody Stability (pdf)
Cell Proliferation/Death Studies (pdf)
Kd Determination- Surface Plasmon Resonance (pdf)
Phage-Display ELISA for Peptide Targets (pdf)
Screening of Candidate Antibodies (pdf)
US FDA Guidelines for Bioanalytical Validation
Rockland Immunochemicals Inc.Gilbertsville, PA 19525E-mail: firstname.lastname@example.orgPhone: 800.656.7625